Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study

被引：20

作者：

Braess, Jan ^{[1
,2
]}

Amler, Susanne ^{[3
,4
]}

Kreuzer, Karl-Anton ^{[5
]}

Spiekermann, Karsten ^{[2
]}

Lindemann, Hans Walter ^{[6
]}

Lengfelder, Eva ^{[7
]}

Graeven, Ullrich ^{[8
]}

Staib, Peter ^{[9
]}

Ludwig, Wolf-Dieter ^{[10
]}

Biersack, Harald ^{[11
]}

Ko, Yon-Dschun ^{[12
]}

Uppenkamp, Michael J. ^{[13
]}

De Wit, Maike ^{[14
]}

Korsten, Stefan ^{[15
]}

Peceny, Rudolf ^{[16
]}

Gaska, Tobias ^{[17
]}

Schiel, Xaver ^{[18
]}

Behringer, Dirk M. ^{[19
]}

Kiehl, Michael G. ^{[20
]}

Zinngrebe, Bettina ^{[21
]}

Meckenstock, Gerald ^{[22
]}

Roemer, Eva ^{[23
]}

Medgenberg, Dirk ^{[24
]}

Spaeth-Schwalbe, Ernst ^{[25
]}

Massenkeil, Gero ^{[26
]}

Hindahl, Heidrun ^{[27
]}

Schwerdtfeger, Rainer ^{[28
]}

Trenn, Guido ^{[29
]}

Sauerland, Cristina ^{[3
]}

Koch, Raphael ^{[3
]}

Lablans, Martin ^{[3
,30
]}

Faldum, Andreas ^{[3
]}

Goerlich, Dennis ^{[3
]}

Bohlander, Stefan K. ^{[2
,31
]}

Schneider, Stephanie ^{[2
]}

Dufour, Annika ^{[2
]}

Buske, Christian ^{[2
,32
]}

Fiegl, Michael ^{[2
]}

Subklewe, Marion ^{[2
]}

Braess, Birgit ^{[1
,2
]}

Unterhalt, Michael ^{[2
]}

Baumgartner, Anja ^{[2
]}

Woermann, Bernhard ^{[33
]}

Beelen, Dietrich ^{[34
]}

Hiddemann, Wolfgang ^{[2
]}

机构：

[1] Hosp Barmherzige Bruder, Dept Oncol & Hematol, Regensburg, Germany

[2] Univ Hosp, Dept Med 3, LMU Campus, Munich, Germany

[3] Univ Hosp, Inst Biostat & Clin Res, Munster, Germany

[4] Fed Res Ctr, Friedrich Loffler Inst, Greifswald, Germany

[5] Univ Hosp, Dept Internal Med 1, Cologne, Germany

[6] Catholic Hosp, Dept Hematol & Oncol, Hagen, Germany

[7] Univ Hosp, Dept Med 3, Mannheim, Germany

[8] Hosp Maria Hilf, Dept Med 1, Monchengladbach, Germany

[9] St Antonius Hosp, Dept Hematol & Med Oncol, Eschweiler, Germany

[10] Helios Hosp, Dept Hematol & Oncol & Tumor Immunol, Berlin, Germany

[11] Univ Hosp, Dept Med 1, Lubeck, Germany

[12] Johanniter Hosp, Dept Med 1, Bonn, Germany

[13] Klinikum Ludwigshafen, Dept Med A, Ludwigshafen, Germany

[14] Vivantes Klinikum Neukolln, Dept Hematol Oncol & Palliat Care, Berlin, Germany

[15] Vinzenz Pallotti Hosp, Dept Med, Bergisch Gladbach, Germany

[16] Klinikum Osnabruck, Dept Hematol & Oncol, Osnabruck, Germany

[17] St Josef Hosp, Dept Hematol & Oncol, Paderborn, Germany

[18] Klinikum Harlaching, Dept Hematol & Oncol, Munich, Germany

[19] Augusta Hosp, Dept Hematol Oncol & Palliat Care, Bochum, Germany

[20] Klinikum Frankfurt Oder, Dept Med 1, Frankfurt, Germany

[21] Evangel Krankenhaus, Dept Hematol Oncol & Palliat Care, Bielefeld, Germany

[22] St Josef Hosp, Dept Med Oncol Radiooncol Hematol & Palliat Care, Gelsenkirchen, Germany

[23] Klinikum Idar Oberstein, Dept Hematol & Oncol, Idar Oberstein, Germany

[24] Klinikum Leverkusen, Dept Med 3, Leverkusen, Germany

[25] Vivantes Klinikum Spandau, Dept Med, Berlin, Germany

[26] Klinikum Gutersloh, Dept Med 2, Gutersloh, Germany

[27] St Johannes Hosp, Dept Med 1, Dortmund, Germany

[28] Deutsch Klin Diagnost, Dept Bone Marrow & Blood Stem Cell Transplantat, Wiesbaden, Germany

[29] Knappschaftskrankenhaus, Dept Med 1, Bottrop, Germany

[30] DKFZ German Canc Res Ctr, Div Med Informat Translat Oncol, Heidelberg, Germany

[31] Univ Auckland, Dept Mol Med & Pathol, Auckland, New Zealand

[32] Univ Hosp, Inst Expt Canc Res, Ulm, Germany

[33] German Soc Hematol & Oncol DGHO, Berlin, Germany

[34] Univ Hosp, Dept Bone Marrow Transplantat, Essen, Germany

来源：

LEUKEMIA | 2018年 / 32卷 / 12期

关键词：

CYTOSINE-ARABINOSIDE; CRITICAL NEUTROPENIA; SALVAGE THERAPY; ADULTS; DIAGNOSIS; AML; TRANSPLANTATION; RECOMMENDATIONS; CONSOLIDATION; CHEMOTHERAPY;

D O I：

10.1038/s41375-018-0268-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Dose-dense induction with the S-HAM regimen was compared to standard double induction therapy in adult patients with newly diagnosed acute myeloid leukemia. Patients were centrally randomized (1:1) between S-HAM (2nd chemotherapy cycle starting on day 8 - "dose-dense") and double induction with TAD-HAM or HAM(-HAM) (2nd cycle starting on day 21 - "standard"). 387 evaluable patients were randomly assigned to S-HAM (N - 203) and to standard double induction (N - 184). The primary endpoint overall response rate (ORR) consisting of complete remission (CR) and incomplete remission (CRi) was not significantly different (P = 0.202) between S-HAM (77%) and double induction (72%). The median overall survival was 35 months after S-HAM and 25 months after double induction (P = 0.323). Duration of critical leukopenia was significantly reduced after S-HAM (median 29 days) versus double induction (median 44 days)-P < 0.001. This translated into a significantly shortened duration of hospitalization after S-HAM (median 37 days) as compared to standard induction (median 49 days)-P < 0.001. In conclusion, dose-dense induction therapy with the S-HAM regimen shows favorable trends but no significant differences in ORR and OS compared to standard double induction. S-HAM significantly shortens critical leukopenia and the duration of hospitalization by 2 weeks.

引用

页码：2558 / 2571

页数：14

共 50 条

[1] Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study
Jan Braess
Susanne Amler
Karl-Anton Kreuzer
Karsten Spiekermann
Hans Walter Lindemann
Eva Lengfelder
Ullrich Graeven
Peter Staib
Wolf-Dieter Ludwig
Harald Biersack
Yon-Dschun Ko
Michael J. Uppenkamp
Maike De Wit
Stefan Korsten
Rudolf Peceny
Tobias Gaska
Xaver Schiel
Dirk M. Behringer
Michael G. Kiehl
Bettina Zinngrebe
Gerald Meckenstock
Eva Roemer
Dirk Medgenberg
Ernst Spaeth-Schwalbe
Gero Massenkeil
Heidrun Hindahl
Rainer Schwerdtfeger
Guido Trenn
Cristina Sauerland
Raphael Koch
Martin Lablans
Andreas Faldum
Dennis Görlich
Stefan K. Bohlander
Stephanie Schneider
Annika Dufour
Christian Buske
Michael Fiegl
Marion Subklewe
Birgit Braess
Michael Unterhalt
Anja Baumgartner
Bernhard Wörmann
Dietrich Beelen
Wolfgang Hiddemann
Leukemia, 2018, 32 : 2558 - 2571
[2] A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia
Wang, Amy Y.
Weiner, Howard
Green, Margaret
Chang, Hua
Fulton, Noreen
Larson, Richard A.
Odenike, Olatoyosi
Artz, Andrew S.
Bishop, Michael R.
Godley, Lucy A.
Thirman, Michael J.
Kosuri, Satyajit
Churpek, Jane E.
Curran, Emily
Pettit, Kristen
Stock, Wendy
Liu, Hongtao
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11 : 4
[3] A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia
Amy Y. Wang
Howard Weiner
Margaret Green
Hua Chang
Noreen Fulton
Richard A. Larson
Olatoyosi Odenike
Andrew S. Artz
Michael R. Bishop
Lucy A. Godley
Michael J. Thirman
Satyajit Kosuri
Jane E. Churpek
Emily Curran
Kristen Pettit
Wendy Stock
Hongtao Liu
Journal of Hematology & Oncology, 11
[4] High-dose cytarabine induction for acute myeloid leukemia
Shepherd, JD
Barnett, MJ
Phillips, GL
BLOOD, 1996, 88 (02) : 754 - 754
[5] Timed sequential therapy with high-dose cytarabine and mitoxantrone as an effective and safe induction regimen for acute myeloid leukemia.
Larson, Melissa L.
Burhani, Sakina
Gallas, Kirstin
Katz, Deborah Ann
Hoyt, Maura
Venugopal, Parameswaran
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[6] Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG
Braess, Jan
Spiekermann, Karsten
Staib, Peter
Grueneisen, Andreas
Woermann, Bernhard
Ludwig, Wolf-Dieter
Serve, Hubert
Reichle, Albrecht
Peceny, Rudolf
Oruzio, Daniel
Schmid, Christoph
Schiel, Xaver
Hentrich, Marcus
Sauerland, Christina
Unterhalt, Michael
Fiegl, Michael
Kern, Wolfgang
Buske, Christian
Bohlander, Stefan
Heinecke, Achim
Baurmann, Herrad
Beelen, Dietrich W.
Berdel, Wolfgang E.
Buechner, Thomas
Hiddemann, Wolfgang
BLOOD, 2009, 113 (17) : 3903 - 3910
[7] A randomized study of high-dose cytarabine in induction in acute myeloid leukemia
Bishop, JF
Matthews, JP
Young, GA
Szer, J
Gillett, A
Joshua, D
Bradstock, K
Enno, A
Wolf, MM
Fox, R
Cobcroft, R
Herrmann, R
VanDerWeyden, M
Lowenthal, RM
Page, F
Garson, OM
Juneja, S
BLOOD, 1996, 87 (05) : 1710 - 1717
[8] A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia
Cahill, Kirk E.
Karimi, Yasmin H.
Karrison, Theodore G.
Jain, Nitin
Green, Margaret
Weiner, Howard
Fulton, Noreen
Kadri, Sabah
Godley, Lucy A.
Artz, Andrew S.
Liu, Hongtao
Thirman, Michael J.
Le Beau, Michelle M.
McNerney, Megan E.
Segal, Jeremy
Larson, Richard A.
Stock, Wendy
Odenike, Olatoyosi
BLOOD ADVANCES, 2020, 4 (04) : 599 - 606
[9] Timed sequential therapy with high-dose cytarabine and mitoxantrone as an induction regimen for acute myeloid leukemia:An update on adverse events.
Richardson, Kristin J.
Kollipara, Revathi
Katz, Deborah Ann
Hoyt, Maura
Gallas, Kirstin
Venugopal, Parameswaran
Larson, Melissa L.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[10] Induction chemotherapy with high-dose cytarabine and mitoxantrone in elderly acute myeloid leukemia (AML) patients.
Ramanathan, Muthalagu
Cerny, Jan
Raffel, Glen
Walsh, William Vincent
Woda, Bruce
Miron, Patricia
Nath, Rajneesh
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →